Everson Gregory T
University of Colorado School of Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B-154 Denver, CO 80262, USA.
Clin Liver Dis. 2005 Aug;9(3):473-86, viii. doi: 10.1016/j.cld.2005.05.011.
In 1999, the World Health Organization reported that there were 169.7 million cases of hepatitis C virus (HCV) infection worldwide. There are 212,500 Americans with chronic hepatitis C and cirrhosis, and this number will increase to 375,000 by the year 2015. If one applies the United States rates for proportion of HCV RNA positivity, duration of infection, and time required for development of cirrhosis to the world's population of individuals with HCV, then 7.8 million currently have cirrhosis. By 2015, there will be 13.8 million cases of cirrhosis due to HCV. Management of cirrhosis due to hepatitis C will continue to be a major issue for the foreseeable future for hepatologists, gastroenterologists, and primary care providers throughout the world. This article discusses the current status of antiviral strategies in treating patients who have decompensated chronic hepatitis C before transplantation.
1999年,世界卫生组织报告称,全球丙型肝炎病毒(HCV)感染病例达1.697亿例。美国有21.25万慢性丙型肝炎和肝硬化患者,到2015年这一数字将增至37.5万。如果将美国HCV RNA阳性率、感染持续时间以及肝硬化发展所需时间的比例应用于全球HCV感染者,那么目前有780万人患有肝硬化。到2015年,将有1380万例由HCV导致的肝硬化病例。在可预见的未来,对于世界各地的肝病学家、胃肠病学家和初级保健提供者而言,丙型肝炎所致肝硬化的管理仍将是一个重大问题。本文讨论了移植前失代偿性慢性丙型肝炎患者抗病毒治疗策略的现状。